|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 2/28/19 Evolent Health, Inc. 10-K 12/31/18 134:19M |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.71M
2: EX-10.26 Material Contract HTML 80K
3: EX-21.1 Subsidiaries List HTML 38K
4: EX-23.1 Consent of Experts or Counsel HTML 36K
5: EX-31.1 Certification -- §302 - SOA'02 HTML 45K
6: EX-31.2 Certification -- §302 - SOA'02 HTML 45K
7: EX-32.1 Certification -- §906 - SOA'02 HTML 39K
8: EX-32.2 Certification -- §906 - SOA'02 HTML 39K
15: R1 Document and Entity Information HTML 74K
16: R2 Consolidated Balance Sheets HTML 155K
17: R3 Consolidated Balance Sheets (Parenthetical) HTML 64K
18: R4 Consolidated Statements of Operations and HTML 136K
Comprehensive Income (Loss)
19: R5 Consolidated Statements of Cash Flows HTML 156K
20: R6 Consolidated Statements of Changes in HTML 144K
Shareholders' Equity (Deficit)
21: R7 Organization HTML 47K
22: R8 Basis of Presentation, Summary of Significant HTML 231K
Accounting Policies and Change in Accounting
Principle
23: R9 Recently Issued Accounting Standards HTML 49K
24: R10 Transactions HTML 341K
25: R11 Revenue Recognition HTML 78K
26: R12 Property and Equipment, Net HTML 55K
27: R13 Goodwill and Intangible Assets, Net HTML 135K
28: R14 Long-term Debt HTML 82K
29: R15 Commitments and Contingencies HTML 140K
30: R16 Earnings (Loss) Per Common Share HTML 73K
31: R17 Stock-based Compensation HTML 200K
32: R18 Income Taxes HTML 166K
33: R19 Employee Benefit Plans HTML 40K
34: R20 Investments In and Advances to Equity Method HTML 44K
Investees
35: R21 Non-controlling Interests HTML 68K
36: R22 Fair Value Measurement HTML 148K
37: R23 Related Parties HTML 58K
38: R24 Segment Reporting HTML 252K
39: R25 Claims Reserves HTML 66K
40: R26 Investments HTML 70K
41: R27 Quarterly Results of Operations (Unaudited) HTML 91K
42: R28 Supplemental Cash Flow Information HTML 74K
43: R29 Basis of Presentation, Summary of Significant HTML 207K
Accounting Policies and Change in Accounting
Principle (Policies)
44: R30 Basis of Presentation, Summary of Significant HTML 245K
Accounting Policies and Change in Accounting
Principle (Tables)
45: R31 Transactions (Tables) HTML 240K
46: R32 Revenue Recognition (Tables) HTML 63K
47: R33 Property and Equipment, Net (Tables) HTML 54K
48: R34 Goodwill and Intangible Assets, Net (Tables) HTML 126K
49: R35 Long-term Debt (Tables) HTML 56K
50: R36 Commitments and Contingencies (Tables) HTML 102K
51: R37 Earnings (Loss) Per Common Share (Tables) HTML 76K
52: R38 Stock-based Compensation (Tables) HTML 185K
53: R39 Income Taxes (Tables) HTML 159K
54: R40 Non-controlling Interests (Tables) HTML 51K
55: R41 Fair Value Measurement (Tables) HTML 193K
56: R42 Related Parties Related Parties (Tables) HTML 53K
57: R43 Segment Reporting (Tables) HTML 246K
58: R44 Claims Reserves (Tables) HTML 60K
59: R45 Investments (Tables) HTML 69K
60: R46 Quarterly Results of Operations (Unaudited) HTML 88K
(Tables)
61: R47 Supplemental Cash Flow Information (Tables) HTML 73K
62: R48 Organization (Details) HTML 78K
63: R49 Basis of Presentation, Summary of Significant HTML 38K
Accounting Policies and Change in Accounting
Principle - Operating Segments (Details)
64: R50 Basis of Presentation, Summary of Significant HTML 86K
Accounting Policies and Change in Accounting
Principle - Restricted Cash and Restricted
Investments (Details)
65: R51 Basis of Presentation, Summary of Significant HTML 55K
Accounting Policies and Change in Accounting
Principle - Notes Receivable (Details)
66: R52 Basis of Presentation, Summary of Significant HTML 47K
Accounting Policies and Change in Accounting
Principle - Estimated Useful Life of Property,
Plant and Equipment (Details)
67: R53 Basis of Presentation, Summary of Significant HTML 40K
Accounting Policies and Change in Accounting
Principle - Research and Development Costs
(Details)
68: R54 Basis of Presentation, Summary of Significant HTML 38K
Accounting Policies and Change in Accounting
Principle - Goodwill (Details)
69: R55 Basis of Presentation, Summary of Significant HTML 50K
Accounting Policies and Change in Accounting
Principle - Intangible Assets, Net (Details)
70: R56 Basis of Presentation, Summary of Significant HTML 40K
Accounting Policies and Change in Accounting
Principle - Impairment of Equity Method
Investments (Details)
71: R57 Basis of Presentation, Summary of Significant HTML 41K
Accounting Policies and Change in Accounting
Principle - Stock-based Compensation (Details)
72: R58 Basis of Presentation, Summary of Significant HTML 44K
Accounting Policies and Change in Accounting
Principle - Foreign Currency (Details)
73: R59 Basis of Presentation, Summary of Significant HTML 137K
Accounting Policies and Change in Accounting
Principle - Change in Accounting Principle
(Details)
74: R60 Recently Issued Accounting Standards (Details) HTML 44K
75: R61 Transactions - New Century Health (Details) HTML 151K
76: R62 Transactions - New Mexico Health Connections HTML 76K
(Details)
77: R63 Transactions - Aldera (Details) HTML 194K
78: R64 Transactions - Valence Health (Details) HTML 268K
79: R65 Transactions - Passport (Details) HTML 81K
80: R66 Transactions - Pro Forma Information (Unaudited) HTML 67K
(Details)
81: R67 Transactions - Securities Offerings and Sales HTML 144K
(Details)
82: R68 Transactions - Asset Acquisitions (Details) HTML 64K
83: R69 Revenue Recognition - Disaggregation of Revenue HTML 55K
(Details)
84: R70 Revenue Recognition - Transaction Price Allocated HTML 42K
to the Remaining Performance Obligations (Details)
85: R71 Revenue Recognition - Contract Balances (Details) HTML 66K
86: R72 Revenue Recognition - Contract Costs (Details) HTML 49K
87: R73 Property and Equipment, Net (Details) HTML 64K
88: R74 Goodwill and Intangible Assets, Net (Details) HTML 95K
89: R75 Goodwill and Intangible Assets, Net - Schedule of HTML 56K
Goodwill (Details)
90: R76 Goodwill and Intangible Assets, Net - Intangible HTML 93K
Assets, Net (Details)
91: R77 Long-term Debt - 2025 Notes (Details) HTML 88K
92: R78 Long-term Debt - 2021 Notes (Details) HTML 74K
93: R79 Long-term Debt - Convertible Senior Notes Carrying HTML 62K
Value (Details)
94: R80 Commitments and Contingencies - Additional HTML 184K
Information (Details)
95: R81 Commitments and Contingencies - Lease Abandonment HTML 48K
Liability (Details)
96: R82 Commitments and Contingencies - Future Minimum HTML 57K
Rental Commitments/Receivables (Details)
97: R83 Commitments and Contingencies - Purchase HTML 46K
Obligations (Details)
98: R84 Commitments and Contingencies - Reinsurance HTML 48K
Agreements (Details)
99: R85 Commitments and Contingencies - Concentration Risk HTML 71K
(Details)
100: R86 Earnings (Loss) Per Common Share - Computation of HTML 70K
Earnings per Share (Details)
101: R87 Earnings (Loss) Per Common Share - Antidilutive HTML 51K
Securities (Details)
102: R88 Stock-based Compensation - 2011 and 2015 Equity HTML 61K
Incentive Plans (Details)
103: R89 Stock-based Compensation - Stock-based HTML 60K
Compensation Expense (Details)
104: R90 Stock-based Compensation - Unrecognized HTML 56K
Compensation Expense (Details)
105: R91 Stock-based Compensation - Stock Options (Details) HTML 70K
106: R92 Stock-based Compensation - Stock Option Activity HTML 91K
(Details)
107: R93 Stock-based Compensation - Performance-based Stock HTML 111K
Option Awards (Details)
108: R94 Stock-based Compensation - Restricted Stock Units HTML 102K
(Details)
109: R95 Income Taxes - Income Tax Expense (Benefit) HTML 72K
(Details)
110: R96 Income Taxes - Reconciliation of Statutory Rate to HTML 82K
Effective Tax Rate (Details)
111: R97 Income Taxes - Deferred Tax Assets and Liabilities HTML 70K
(Details)
112: R98 Income Taxes - Changes in Valuation Allowance HTML 47K
(Details)
113: R99 Income Taxes (Details) HTML 61K
114: R100 Income Taxes - Changes In Unrecognized Tax HTML 50K
Benefits (Details)
115: R101 Employee Benefit Plans (Details) HTML 38K
116: R102 Investments In and Advances to Equity Method HTML 53K
Investees (Details)
117: R103 Non-controlling Interests (Details) HTML 164K
118: R104 Fair Value Measurement - Assets and Liabilities on HTML 66K
Recurring Basis (Details)
119: R105 Fair Value Measurement (Details) HTML 47K
120: R106 Fair Value Measurement - Changes in Contingent HTML 45K
Consideration and Other (Details)
121: R107 Fair Value Measurement - Valuation Techniques and HTML 72K
Significant Unobservable Inputs (Details)
122: R108 Related Parties (Details) HTML 41K
123: R109 Related Parties - Revenues and Expenses (Details) HTML 65K
124: R110 Segment Reporting (Details) HTML 167K
125: R111 Segment Reporting - Reconciliation of Adjusted HTML 95K
EBITDA (Details)
126: R112 Claims Reserves (Details) HTML 71K
127: R113 Investments - Investment Summary (Details) HTML 61K
128: R114 Investments - Contractual Maturity (Details) HTML 56K
129: R115 Quarterly Results of Operations (Unaudited) HTML 65K
(Details)
130: R116 Quarterly Results of Operations (unaudited) - HTML 44K
Additional Information (Details)
131: R117 Supplemental Cash Flow Information (Details) HTML 84K
133: XML IDEA XML File -- Filing Summary XML 254K
132: EXCEL IDEA Workbook of Financial Reports XLSX 186K
9: EX-101.INS XBRL Instance -- evh-20181231 XML 5.95M
11: EX-101.CAL XBRL Calculations -- evh-20181231_cal XML 395K
12: EX-101.DEF XBRL Definitions -- evh-20181231_def XML 1.72M
13: EX-101.LAB XBRL Labels -- evh-20181231_lab XML 2.91M
14: EX-101.PRE XBRL Presentations -- evh-20181231_pre XML 2.18M
10: EX-101.SCH XBRL Schema -- evh-20181231 XSD 297K
134: ZIP XBRL Zipped Folder -- 0001628908-19-000006-xbrl Zip 515K
| Exhibit |
1. | I have reviewed this Annual Report on Form 10-K of Evolent Health, Inc.; |
2. | Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The
registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including
its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c. | Evaluated
the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d. | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the
registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. | The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the
registrant’s board of directors (or persons performing the equivalent functions): |
a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
b. | Any
fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Dated: | /s/ Nicholas McGrane | ||
Name: Nicholas
McGrane | |||
Title: Chief Financial Officer | |||
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 2/28/19 | None on these Dates | ||
| For Period end: | 12/31/18 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/23/24 Evolent Health, Inc. 10-K 12/31/23 144:17M 2/24/23 Evolent Health, Inc. 10-K 12/31/22 148:19M 2/24/22 Evolent Health, Inc. 10-K 12/31/21 154:19M 2/26/21 Evolent Health, Inc. 10-K 12/31/20 152:19M |